Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04718571 |
| Other study ID # |
2020-00872 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
August 1, 2020 |
| Est. completion date |
December 1, 2020 |
Study information
| Verified date |
January 2021 |
| Source |
University Hospital, Geneva |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Prevalence of NTM diseases has been increasing regularly over the past 30 years in
industrialized countries Although NTM are identified worldwide, there are important
geographical disparities as to the relative prevalence of NTM species There are no data
covering the ecology of NTM in Switzerland. Because of the progressive increase in NTM
clinical cases in area Geneva(as noted in other industrialized countries), reporting the
specific NTM distribution is important and relevant. In this study, the investigators aimed
to: 1/ describe the relative prevalence of NTM species in clinical samples analyzed in the
Geneva area, covering ca 500'000 inhabitants over a 5-year period; 2/ determine how many
culture positive patients were treated; and 3/ specify the clinical sites involved.
Description:
This study was performed in the Geneva University Hospitals (HUG), a 2008-bed complex
providing care for a population of ca. 500'000 inhabitants. All clinical samples sent for
microbiological analysis within HUG are treated by the Bacteriology Laboratory of Geneva
University Hospitals. An online database is kept up-to-date and includes all samples
processed by the laboratory. The investigators performed a comprehensive analysis of all
clinical samples included in this database over a 5-year period (2015-2020). This report
focuses only on positive results for nontuberculous mycobacteria (NTM).The following items
were recorded: age, gender, BMI whenever available, site of infection (when pulmonary:
description of main radiological abnormalities), presence and type of immunosuppression,
relevant pulmonary and non-pulmonary comorbidities, results of microscopy, and NTM species
identified. The investigators also recorded whether the patient was treated for the
identified NTM or not and if a susceptibility profile had been determined (this is not
routinely performed and must be requested by the clinician).
The study protocol was approved by their local ethics committee
